Department of Molecular Oncology

Department head: Professor Ragnhild A. Lothe
Deputy department head: Professor Rolf I. Skotheim
Laboratory manager: Professor Guro E. Lind
Department administrative consultant: Ikram Mahnin

Scientific achievements at Dept Molecular Oncology in 2019

Research groups

Genetics Genome Biology Epigenetics
Ragnhild A. Lothe
Rolf I. Skotheim
Guro E. Lind

Project groups

Computational Oncology  Cancer Informatics  
Anita Sveen
Bjarne Johannessen
Marine Jeanmougin
Cell Signalling    
Edward Leithe
   

 

As a research department within the OUH Comprehensive Cancer Centre, it is our responsibility and goal to accomplish high quality and interdisciplinary biomedical research for improved precision medicine and management of cancer patients.

About

Our main research programs are devoted to colorectal cancer and prostate cancer, and we have a longstanding project portfolio also on other solid tumor types. Our expertise in biomedical research spans several disciplines from cell biology to translational research, including also active clinical research collaborations, and we have a broad range of advanced technologies established in-lab. The department scientists are inventors of several biomedical patents and active innovation projects.

Lothe lab – genetics, genomics, cell signaling, colorectal cancer, MPNST, tumor heterogeneity, pharmacogenomics, biomarkers

Skotheim lab – genome biology, transcript variation, tumor heterogeneity, prostate cancer, testicular cancer, bioinformatics

Lind lab – epigenetics, genetics, GI-cancers, bladder cancer, early detection, monitoring

Affiliations

All three group leaders are adjunct professors at the University of Oslo and are affiliated with the Institute for Clinical Medicine, the Institute for Biosciences and the Institute for Informatics. We aim to complete at least 3 academic degrees annually, and since the inauguration of the Department in 2006, 59 MSc/PhD degrees have successfully been defended.

The research groups are partners of the K. G. Jebsen Colorectal Cancer Research Centre (led by Prof. Lothe), the OUH priority area for colorectal cancer, the Norwegian Cancer Genomics Consortium, the European network for study on Cholangiocarcinoma, and the Global Testicular Cancer Consortium.

The K.G. Jebsen Colorectal Cancer Research Centre.


Latest News

The cancer patient’s own drug sensitivity model

From left: Eide, Kryeziu and Bruun.

The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. 

Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors , and have established the PDO lineages and drug screen analyses.

Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research

Jørgen Smeby during the digital PhD defence

The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020.

Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo.

The work was performed in the Lothe lab at the Institute for Cancer Research. 

Kaja Christine Graue Berg defended her PhD on the 10th Dec 2019

She has performed her work in the Lothe lab., and has been a PhD student at the Institute for Clinical Medicine, Faculty of Medicine, U of Oslo.

The thesis  “Integrated genomics of colorectal cancer” included three papers of which she is the 1st author (Molecular Cancer 2017, Oncogene 2019, submitted manuscript).

The candidate held an excellent trial lecture “The gut microbiome as an emerging target for cancer therapy”, and she had a good discussion with her two opponents professors Karin Jirstrøm and Eirik Frengen (photo, candidate to the right).

Young researcher award to Peter Wold Eide at “Onkologisk Forum”

Peter W. Eide
Peter W. Eide

Dr. Peter Wold Eide, post doc in the Lothe lab received the "Young researcher award" for his scientific accomplishments during the 2019 Onkologisk forum held in Tromsø November 21st-22nd where he presented a lecture entitled "Fra generiske kreftmodeller til klinisk medikamentscreening”.

Guro E. Lind new leader of The Norwegian Association of Researchers (Forskerforbundet)

Guro E. Lind
Guro E. Lind

Professor Guro Elisabeth Lind, head of the Epigentics research group at the Department of Molecular Oncology, has been elected as new leader in "Forskerforbundet" - The Norwegian Association of Researchers, taking over January 1st 2019.

Lind is a former head of "Akademiet for yngre forskere" (The Young Academy of Norway) and has also been a local representative for Forskerforbundet. She will be the first female leader since the 80's, and replaces Petter Aaslestad, who has been in charge of the Research Association for the last six years (two periods).

"I was very much in doubt, first and foremost because I am an active researcher with a research group and exciting projects. But I am also actively engaged in research policy and could not say no to this exciting challenge", Lind says to Khrono.

The 2019 Oslo University Hospital Researcher Awards to Andreassen, Kalager and Sveen

Ole Andreassen, Merete Kalager and Anita Sveen (photo: Dag Kristiansen).

Three scientists received awards for their outstanding research at a ceremony taking place at Oslo University Hospital August 23rd. 

The major prize - the "Excellent Researcher Award" - went to Ole A. Andreassen. Mette Kalager and Anita Sveen both received the "Early Career Award".

Skotheim group publishes important prostate cancer study in prestigious journal: High degree of genomic heterogeneity in multifocal primary prostate cancer

Marthe LøvfFirst author
Marthe Løvf
First author

The vast majority of primary prostate cancers are multifocal. The individual tumors within the prostate gland are known to have different aggressiveness and develop independently of one another, but little has been known about their genetic relationship.

Marthe Løvf and colleagues have performed the first large in-depth genomic heterogeneity study of primary prostate cancer and the results were published in the recognized journal European Urology earlier this month. The researchers performed exome sequencing of 89 tumor foci from 41 patients and demonstrated convincingly that the different foci within the same patient only exceptionally have any somatic gene mutations in common.

Postdoctor Andreas M. Hoff is shared first-author New publication in Cell on structural genome alterations driving castration-resistant prostate cancer

Andreas M. Hoff
Andreas M. Hoff

Postdoctor Andreas M. Hoff in the Skotheim group at the Department of Molecular Oncology spent a year of his postdoc in the lab of Matthew Meyerson at the Broad Institute and Dana Farber Cancer Institute, Boston, USA. As shared first-author, he publishes together with his colleagues at the Meyerson lab in the prestigous journal Cell (impact factor 30).